亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy

医学 内科学 肺癌 肿瘤科 危险系数 化疗 临床试验 化学免疫疗法 癌症 杜瓦卢马布 实体瘤疗效评价标准 免疫疗法 临床研究阶段 外科 置信区间 无容量
作者
Tafadzwa L. Chaunzwa,Jack M. Qian,Qin Li,Biagio Ricciuti,Leonard Nuernberg,Justin W. Johnson,Jakob Weiß,Zhongyi Zhang,J. Mackay,Ioannis Kagiampakis,Damián E. Bikiel,Alessandro Di Federico,Joao V. Alessi,Raymond H. Mak,Etai Jacob,Mark M. Awad,Hugo J.W.L. Aerts
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:10 (6): 773-773 被引量:35
标识
DOI:10.1001/jamaoncol.2024.1120
摘要

Importance: The association between body composition (BC) and cancer outcomes is complex and incompletely understood. Previous research in non-small-cell lung cancer (NSCLC) has been limited to small, single-institution studies and yielded promising, albeit heterogeneous, results. Objectives: To evaluate the association of BC with oncologic outcomes in patients receiving immunotherapy for advanced or metastatic NSCLC. Design, Setting, and Participants: This comprehensive multicohort analysis included clinical data from cohorts receiving treatment at the Dana-Farber Brigham Cancer Center (DFBCC) who received immunotherapy given alone or in combination with chemotherapy and prospectively collected data from the phase 1/2 Study 1108 and the chemotherapy arm of the phase 3 MYSTIC trial. Baseline and follow-up computed tomography (CT) scans were collected and analyzed using deep neural networks for automatic L3 slice selection and body compartment segmentation (skeletal muscle [SM], subcutaneous adipose tissue [SAT], and visceral adipose tissue). Outcomes were compared based on baseline BC measures or their change at the first follow-up scan. The data were analyzed between July 2022 and April 2023. Main Outcomes and Measures: Hazard ratios (HRs) for the association of BC measurements with overall survival (OS) and progression-free survival (PFS). Results: A total of 1791 patients (878 women [49%]) with NSCLC were analyzed, of whom 487 (27.2%) received chemoimmunotherapy at DFBCC (DFBCC-CIO), 825 (46.1%) received ICI monotherapy at DFBCC (DFBCC-IO), 222 (12.4%) were treated with durvalumab monotherapy on Study 1108, and 257 (14.3%) were treated with chemotherapy on MYSTIC; median (IQR) ages were 65 (58-74), 66 (57-71), 65 (26-87), and 63 (30-84) years, respectively. A loss in SM mass, as indicated by a change in the L3 SM area, was associated with worse oncologic outcome across patient groups (HR, 0.59 [95% CI, 0.43-0.81] and 0.61 [95% CI, 0.47-0.79] for OS and PFS, respectively, in DFBCC-CIO; HR, 0.74 [95% CI, 0.60-0.91] for OS in DFBCC-IO; HR, 0.46 [95% CI, 0.33-0.64] and 0.47 [95% CI, 0.34-0.64] for OS and PFS, respectively, in Study 1108; HR, 0.76 [95% CI, 0.61-0.96] for PFS in the MYSTIC trial). This association was most prominent among male patients, with a nonsignificant association among female patients in the MYSTIC trial and DFBCC-CIO cohorts on Kaplan-Meier analysis. An increase of more than 5% in SAT density, as quantified by the average CT attenuation in Hounsfield units of the SAT compartment, was associated with poorer OS in 3 patient cohorts (HR, 0.61 [95% CI, 0.43-0.86] for DFBCC-CIO; HR, 0.62 [95% CI, 0.49-0.79] for DFBCC-IO; and HR, 0.56 [95% CI, 0.40-0.77] for Study 1108). The change in SAT density was also associated with PFS for DFBCC-CIO (HR, 0.73; 95% CI, 0.54-0.97). This was primarily observed in female patients on Kaplan-Meier analysis. Conclusions and Relevance: The results of this multicohort study suggest that loss in SM mass during systemic therapy for NSCLC is a marker of poor outcomes, especially in male patients. SAT density changes are also associated with prognosis, particularly in female patients. Automated CT-derived BC measurements should be considered in determining NSCLC prognosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
情怀的应助被whc采纳,获得10
20秒前
shoemaker完成签到,获得积分10
25秒前
26秒前
阿辉完成签到,获得积分10
27秒前
27秒前
whc发布了新的文献求助10
32秒前
whc完成签到,获得积分10
38秒前
39秒前
张阳发布了新的文献求助10
42秒前
生尽证提发布了新的文献求助10
43秒前
生尽证提完成签到,获得积分10
50秒前
李爱国的应助被张阳采纳,获得10
56秒前
老实大炮完成签到,获得积分10
1分钟前
zzZ_完成签到 ,获得积分10
1分钟前
1分钟前
佳佳发布了新的文献求助10
1分钟前
多情的棒棒糖完成签到,获得积分10
1分钟前
温暖的忆霜完成签到,获得积分10
1分钟前
1分钟前
PDJJ完成签到 ,获得积分10
1分钟前
1分钟前
甜甜的黑猫完成签到,获得积分10
1分钟前
Maestro_S的应助被科研通管家采纳,获得30
1分钟前
caspar发布了新的文献求助10
1分钟前
caspar完成签到,获得积分10
2分钟前
华仔的应助被佳佳采纳,获得10
2分钟前
干净的醉蝶完成签到,获得积分10
2分钟前
hamburger完成签到,获得积分10
2分钟前
欢喜的铭完成签到,获得积分10
3分钟前
3分钟前
张阳发布了新的文献求助10
3分钟前
风趣香岚完成签到,获得积分10
3分钟前
3分钟前
3分钟前
陈荆洲完成签到,获得积分10
4分钟前
4分钟前
心想事橙完成签到 ,获得积分10
4分钟前
佳佳发布了新的文献求助10
4分钟前
4分钟前
传奇3的应助被gtgyh采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190136
求助须知:如何正确求助?哪些是违规求助? 9577239
关于积分的说明 21852212
捐赠科研通 7788483
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2560043
邀请新用户注册赠送积分活动 2482880